Results 31 to 40 of about 656,371 (370)
Molecular dynamics and optimization studies of horse prion protein wild type and its S167D mutant [PDF]
MDPI journal Zoonotic Diseases 4(3):187-200 (2024), 2021 Prion diseases or called transmissible spongiform encephalopathies are fatal neurodegenerative diseases characterised by the accumulation of an abnormal prion protein isoform (rich in beta-sheets - about 30% alpha-helix and 43% beta-sheet), which is converted from the normal prion protein (predominant in alpha-helix - about 42% alpha-helix and 3% beta ...
arxiv +1 more source
Minimal residual disease in EGFR-mutant non-small-cell lung cancer
Frontiers in Oncology, 2022 Targeted therapy with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) is an effective treatment for EGFR-mutant non-small-cell lung cancer (NSCLC), however most patients invariably relapse after a period of minimal residual ...
Nathan T. Bain +5 more
doaj +1 more source
Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors [PDF]
, 2002 FLT3 mutations, either internal tandem duplications (ITDs) or aspartate residue 835 (D835) point mutations, are present in approximately one third of patients with acute myeloid leukemia (AML) and have been associated with an increased relapse rate.
Bowen, D.T. +5 more
core +1 more source
Cellular residual disease (CRD) in early breast cancer –Expanding the concept of minimal residual disease monitoring? [PDF]
, 2023 Despite a significant evolution in treatment strategies for early breast cancer (EBC) patients, up to 30% of them experience recurrence due to occult micrometastasis.
Carolina Reduzzi +5 more
core +1 more source
Minimal Residual Disease [PDF]
Leukemia Supplements, 2003 The aim of minimal residual disease (MRD) studies in patients with acute leukemia is to measure initial treatment response accurately, provide an assessment of the residual leukemic burden throughout therapy and detect relapse early. Therefore, information resulting from MRD monitoring can substantially improve many facets of clinical management ...
openaire +3 more sources
Cancers, 2021 Simple Summary Minimal residual disease (MRD) represents a status of the disease which is assumed to still be present in the body until it is clinically observed by radiology.
L. Larribère, U. Martens
semanticscholar +1 more source
Haematologica, 2012 Background In the present study, the prognostic impact of minimal residual disease during treatment on time to progression and overall survival was analyzed prospectively in patients with mantle cell lymphoma treated on the Cancer and Leukemia Group B ...
Hongtao Liu +10 more
doaj +1 more source
Re: Molecular testing to deliver personalised chemotherapy recommendations
BMC Medicine, 2023 Background There is an increasing focus over time on the discovery and validation of biomarkers in cancer medicine, which can inform the identification of patients that are most likely to benefit from treatment, which therapy is most likely to be ...
Peter Gibbs, Wei Hong, Jeanne Tie
doaj +1 more source
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis [PDF]
, 2017 Minimal residual disease prior to allogeneic hematopoietic cell transplantation has been associated with increased risk of relapse and death in patients with acute myeloid leukemia, but detection methodologies and results vary widely.
Anthias, Chloe +14 more
core +2 more sources
Blood Cancer Journal, 2021 Light chain (AL) amyloidosis is caused by a small B-cell clone producing light chains that form amyloid deposits and cause organ dysfunction. Chemotherapy aims at suppressing the production of the toxic light chain (LC) and restore organ function ...
G. Palladini +24 more
semanticscholar +1 more source